Analyst consensus rating
Latigo Biotherapeutics Analyst Rating: Strong Buy
Direct answer
Latigo Biotherapeutics's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $52.25.
Forecast evidence checked September 5, 2026.
Get free Latigo Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $23.04
- Average price target
- $52.25
- High price target
- $73.00
- Low price target
- $36.00
- Low target gap
- +56.3%
- Target upside
- +126.8%
- High target gap
- +216.8%
- Target range width
- 160.6%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Latigo Biotherapeutics?
Latigo Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $52.25.
How far are Latigo Biotherapeutics's low and high targets from the recorded price?
The low target implies +56.3%, while the high target implies +216.8%.
How many analysts are included in Latigo Biotherapeutics's consensus?
The verified consensus includes 4 analysts.
How is Latigo Biotherapeutics's target upside or downside calculated?
The average target of $52.25 is divided by the recorded price of $23.04, then one is subtracted to produce +126.8%. This does not guarantee a future return.
When was Latigo Biotherapeutics's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.